

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of claims:**

1-30. (canceled)

31. (previously presented) A method of treating cancer comprising administering to an individual in need thereof an effective amount of a composition comprising a *Quillaja saponaria* saponin, wherein said effective amount stimulates innate immunity, thereby treating said cancer, and wherein said composition does not contain a vaccine antigen.

32. (canceled)

33. (previously presented) The method as claimed in claim 31, wherein said *Quillaja saponaria* saponin is chemically modified.

34. (previously presented) The method as claimed in claim 31, wherein said *Quillaja saponaria* saponin is substantially pure.

35. (previously presented) The method as claimed in claim 34, wherein said substantially pure *Quillaja saponaria* saponin is QS-7, QS-17, QS-18, or QS-21.

36. (previously presented) The method as claimed in claim 35, wherein said substantially pure *Quillaja saponaria* saponin is QS-21.

37. (previously presented) The method as claimed in claim 31, wherein said individual is a mammal.

38. (previously presented) The method as claimed in claim 31, wherein said individual is a human.

39. (canceled)

40. (previously presented) The method as claimed in claim 31, wherein said effective amount of a composition comprising a *Quillaja saponaria* saponin is an amount sufficient to enhances a natural killer cell response.

41-43. (canceled)

44. (previously presented) The method as claimed in claim 40, wherein said enhanced natural killer cell response is evaluated by an *in vitro* assay comprising:

(a) contacting natural killer cell-sensitive target cells with effector cells, wherein said effector cells are from said individual that has been administered said composition; and

(b) determining the level of lysis of said natural killer cell-sensitive target cells; wherein increased lysis of natural killer cell-sensitive target cells contacted with effector cells from said individual that has been administered said composition as compared to natural killer cell-sensitive target cells contacted with effector cells from an individual that has not been administered said composition indicates an enhanced natural killer cell response.

45. (previously presented) The method as claimed in claim 31, 33, 34, 35, 36, 37, 38 or 40, wherein said composition does not contain an oligonucleotide comprising at least one unmethylated CpG dinucleotide.

46. (previously presented) The method as claimed in claim 31, 33, 34, 35, 36, 37, 38 or 40, wherein said composition further comprises an oligonucleotide comprising at least one unmethylated CpG dinucleotide.